Giovanni L. Ceresoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giovanni L. Ceresoli has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Armando Santoro
1 shared publication- Armando Santoro
Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano (Milan), Italy
1 shared publication Cristina Ripa
1 shared publicationElena Lorenzi
1 shared publication- Elisabetta Campagnoli
Dipartimento di Oncologia Medica e Ematologia, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, 20089, Rozzano, MI, Italy
1 shared publication Fabio De Vincenzo
1 shared publication
Latest Publications
- 1 April 2011
- Published by Elsevier in Lung Cancer
- Vol. 72 (1) , 73-77
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
- 1 April 2011
- Published by Elsevier in Lung Cancer
- Vol. 72 (1) , 73-77
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
- 23 October 2007
- Published by Informa Healthcare in Expert Opinion on Medical Diagnostics
- Vol. 1 (2) , 183-191
EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?
The EGF receptor (EGFR) is one of the most important targets for cancer treatment implicated in the control of cell survival, proliferation and metastasis. In the last few years different EGFR molecular antagonists have been evaluated in the clinical setting and some of these drugs have demonstrated clinical efficacy in a subset of non-small cell lung cancer (NSCLC) patients. Gefitinib or erlotinib are a new class of compounds able to inhibit the tyrosine kinase domain of EGFR (EGFR TKI) and, during recent years, clinical and biologic predictors for TKI sensitivity have been identified. Among clinical features, never-smoking history has emerged as the most relevant clinical characteristic predictive of response to TKIs in NSCLC, and EGFR gene mutation or EGFR increased gene copy number represent critical biologic variables associated with an improved outcome for patients exposed to these agents. Unfortunately, cancer cells possess escape mechanisms to overcome inhibition of cell proliferation leading to drug resistance. There are several mechanisms that have been identified as responsible for intrinsic or acquired resistance. The aim of the present review is to analyze available data in order to identify an optimal paradigm for patient selection.
- 23 October 2007
- Published by Informa Healthcare in Expert Opinion on Medical Diagnostics
- Vol. 1 (2) , 183-191
EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?
The EGF receptor (EGFR) is one of the most important targets for cancer treatment implicated in the control of cell survival, proliferation and metastasis. In the last few years different EGFR molecular antagonists have been evaluated in the clinical setting and some of these drugs have demonstrated clinical efficacy in a subset of non-small cell lung cancer (NSCLC) patients. Gefitinib or erlotinib are a new class of compounds able to inhibit the tyrosine kinase domain of EGFR (EGFR TKI) and, during recent years, clinical and biologic predictors for TKI sensitivity have been identified. Among clinical features, never-smoking history has emerged as the most relevant clinical characteristic predictive of response to TKIs in NSCLC, and EGFR gene mutation or EGFR increased gene copy number represent critical biologic variables associated with an improved outcome for patients exposed to these agents. Unfortunately, cancer cells possess escape mechanisms to overcome inhibition of cell proliferation leading to drug resistance. There are several mechanisms that have been identified as responsible for intrinsic or acquired resistance. The aim of the present review is to analyze available data in order to identify an optimal paradigm for patient selection.